Search Result

Results for "

cytoskeletal

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Aldehyde Dehydrogenase (ALDH) (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (1) Apoptosis (9) Arp2/3 Complex (2) Bacterial (2) Bcl-2 Family (2) Biochemical Assay Reagents (3) Calcium Channel (2) Caspase (2) CCR (1) CDK (1) Checkpoint Kinase (Chk) (1) Choline Kinase (1) Disulfidptosis (3) DNA/RNA Synthesis (1) Drug Derivative (1) Endogenous Metabolite (2) Environmental Pollutants (1) Fungal (3) G Protein-coupled Receptor Kinase (GRK) (1) GLUT (3) Isotope-Labeled Compounds (2) JNK (2) MDM-2/p53 (1) Microtubule/Tubulin (5) Mixed Lineage Kinase (1) mRNA (1) Myosin (1) p38 MAPK (2) PAK (3) PDGFR (1) PERK (2) Phospholipase (2) PI3K (1) PROTACs (1) Ras (3) Reactive Oxygen Species (ROS) (2) Reference Standards (2) ROCK (4) SOD (1) STAT (1) TRP Channel (1) Wee1 (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (22) Cardiovascular Disease (5) Endocrinology (1) Infection (5) Inflammation/Immunology (6) Metabolic Disease (6) Neurological Disease (7)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Chemokine & Receptors (1) Phospholipids (1) mRNA (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

BAY-876 Maximum Cited Publications 52 Publications Verification	GLUT Disulfidptosis	Cancer
BAY-876, a chemical probe, is an orally active and selective glucose transporter 1 (GLUT1) inhibitor with an IC₅₀ of 2 nM. BAY-876 is >130-fold more selective for GLUT1 than GLUT2, GLUT3, and GLUT4. BAY-876 is also a potent blocker of glycolytic metabolism and ovarian cancer growth. In addition, BAY-876 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .

i-Inositol 5+ Cited Publications myo-Inositol; meso-Inositol	Endogenous Metabolite	Others
i-Inositol (myo-Inositol) is a compound of sugar alcohols. i-Inositol is involved in a series of biological processes such as insulin signal transduction and cytoskeletal transduction. i-Inositol mainly exists in glial cells and plays an osmotic role .

KL-11743 5 Publications Verification	GLUT Disulfidptosis	Metabolic Disease Cancer
KL-11743 is a potent, orally active, and glucose-competitive inhibitor of the class I glucose transporters, with IC₅₀s of 115, 137, 90, and 68 nM for GLUT1, GLUT2, GLUT3, and GLUT4, respectively. KL-11743 specifically blocks glucose metabolism. KL-11743 can synergize with electron transport inhibitors to induce cell death. In addition, KL-11743 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .

PF-3758309 5+ Cited Publications PF-03758309	PAK Apoptosis	Cancer
PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (K_d= 2.7 nM; K_i=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .

FIPI 5 Publications Verification 5-Fluoro-2-indolyl deschlorohalopemide	Phospholipase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
FIPI is a phospholipase D (PLD) inhibitor with an IC₅₀ for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .

Dextran T3 (MW 3,000) Dextran 3; Dextran D3; Dextran T3(MW 2400-3600)	Bacterial	Others
Dextran T3 (Dextran 3; Dextran T3(MW 2400-3600)) is a neural tracer and intestinal permeability probe that can move anterogradely and retrogradely in neuronal axons by passive diffusion. Dextran T3 (MW 3,000) is able to permeate across the intestinal epithelial cell membrane in the presence of cholera toxin-induced cytoskeletal disturbance. Dextran T3 (MW 3,000) is used as a fluorescent marker to rapidly label developing neurons (such as Xenopus retinal ganglion cells) and to assess intestinal barrier function. It can be used to study axonal transport in neuroanatomy and permeability changes in intestinal pathophysiology. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .

Fludioxonil CGA-173506	Environmental Pollutants Fungal Apoptosis	Infection Cancer
Fludioxonil (CGA-173506) is a phenylpyrrole-type fungicide with oral activity that can inhibit the growth of S. sclerotiorum. Fludioxonil promotes tumor growth and metastasis, and induces cardiac toxicity. Fludioxonil causes cytoskeletal disruption, DNA damage, and apoptosis in mouse glioma cells .

2-Bromoacetamide	Aldehyde Dehydrogenase (ALDH) Microtubule/Tubulin	Metabolic Disease
2-Bromoacetamide is a disinfection byproduct. 2-Bromoacetamide can inactivate liver alcohol dehydrogenase and interfere with microtubule and actin cytoskeletal function. 2-Bromoacetamide is a potent developmental toxicant in animals .

Ristocetin A sulfate Ristomycin III	Antibiotic	Cardiovascular Disease Infection
Ristocetin A sulfate (Ristomycin III) is a glycopeptide antibiotic that binds to von Willebrand factor (VWF) and bacterial cell wall components. Ristocetin A sulfate interferes with the biosynthesis of bacterial peptidoglycan by inhibiting transpeptidation. As an inducer of platelet adhesion and aggregation, Ristocetin A sulfate drives conformational changes by binding to the A1 domain of VWF, thereby activating downstream signaling pathways and promoting cytoskeletal rearrangement. Ristocetin A sulfate not only enhances platelet adhesion and spreading on immobilized VWF, but also induces the formation of asymmetric dimers with anticooperativity between platelets and plasma VWF. Ristocetin A sulfate is widely used in studies related to thromboembolic diseases and bacterial infections .

GFB-8438	TRP Channel	Neurological Disease
GFB-8438 is a potent and subtype selective TRPC5 inhibitor, with IC₅₀s of 0.18 and 0.29 μM of hTRPC5 and hTRPC4, respectively. GFB-8438 shows excellent selectivity against TRPC6, other TRP family members, NaV 1.5, as well as limited activity against the hERG channel. GFB-8438 protects mouse podocytes from injury induced by protamine sulfate model .

Methylophiopogonanone B 2 Publications Verification	Ras Microtubule/Tubulin	Cancer
Methylophiopogonanone B is a homoisoflavonoid compound. Methylophiopogonanone B can be isolated from O. japonicus root. Methylophiopogonanone B promotes Rho activation and Tubulin depolymerization. Methylophiopogonanone B significantly increases GTP-Rho, but not GTP-Rac or GTP-CDC42. Methylophiopogonanone B induces cell morphological change via melanocyte dendrite retraction and stress fiber formation. Methylophiopogonanone B exhibits strong antioxidant activity. Methylophiopogonanone B can be used in the research of cervical cancer .

i-Inositol (Standard) myo-Inositol (Standard); meso-Inositol (Standard)	Reference Standards Endogenous Metabolite	Others
i-Inositol (Standard) is the analytical standard of i-Inositol. This product is intended for research and analytical applications. i-Inositol (myo-Inositol) is a compound of sugar alcohols. i-Inositol is involved in a series of biological processes such as insulin signal transduction and cytoskeletal transduction. i-Inositol mainly exists in glial cells and plays an osmotic role .

Dihydrocytochalasin B	Arp2/3 Complex DNA/RNA Synthesis Calcium Channel	Inflammation/Immunology
Dihydrocytochalasin B is an Actin disruptor. Dihydrocytochalasin B disrupts actin microfilament bundles, inhibits actin polymerization, and alters intracellular actin cytoskeletal structures. Dihydrocytochalasin B blocks the initiation of DNA synthesis. Dihydrocytochalasin B inhibits Calcium transport. Dihydrocytochalasin B inhibits cytokinesis and alters cell morphology. Dihydrocytochalasin B can be used in studies related to rickets .

H-Tyr-Phe-OH L-Tyrosyl-L-phenylalanine	Xanthine Oxidase Angiotensin-converting Enzyme (ACE)	Inflammation/Immunology Cancer
H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells .

Exoenzyme C3, clostridium botulinum	Biochemical Assay Reagents ROCK	Neurological Disease Metabolic Disease
Exoenzyme C3, clostridium botulinum, is a mono-ADP-ribosylating enzyme. Exoenzyme C3, clostridium botulinum specifically modifies RhoA, B, and C by transferring ADP-ribose to them, thereby inactivating these GTPases. Exoenzyme C3, clostridium botulinum can induce neuronal axonal and dendritic growth, inhibit macrophage migration, and regulate cytoskeletal dynamics. Exoenzyme C3, clostridium botulinum can be used in the research of spinal cord injury and diabetic painful neuropathy .

AA-BR-157	PROTACs	Neurological Disease Cancer
AA-BR-157 is a metallothionein 2A (MT2A) PROTAC degrader, DC₅₀ is 200 nM (MT2A overexpressed in MDA-MB-231 cells). AA-BR-157 increases intracellular zinc levels, downregulates DIAPH3, disrupts cytoskeleton remodeling, and reduces the migration and invasion abilities of cancer cells. AA-BR-157 can be used for research on triple-negative breast cancer and glioblastoma .

DAyne	Biochemical Assay Reagents	Neurological Disease
DAyne is a Dopamine (DA)-mimetic probe. DAyne covalently binds to proteins modified by dopamine oxidation products (e.g., dopaquinone, DQ) to form adducts. DAyne is promising for research of Parkinson’s disease (PD), particularly neurotoxicity, protein modification, and related pathways (e.g., endoplasmic reticulum stress, cytoskeletal instability) caused by dopamine dysregulation .

(+)-Perillyl alcohol (R)-(+)-Perillyl alcohol	Ras	Cancer
(+)-Perillyl alcohol is the enantiomer of S-(-)-Perillyl alcohol (HY-116514). (+)-Perillyl alcohol can inhibit the growth of polypeptides and block the cell cycle in the G0/G1 phase. (+)-Perillyl alcohol induces cell signaling that is associated with changes in cytoskeletal actin organization and reduced protein expression of growth regulatory proteins such as Ras and CDC2 kinase .

(E)-2-Hexadecenal 16:1 Aldehyde; trans-2-Hexadecenal	Mixed Lineage Kinase Apoptosis JNK Microtubule/Tubulin	Cancer
(E)-2-Hexadecenal (trans-2-Hexadecenal) is an MLK3 activator that induces cytoskeletal remodeling, leading to cell rounding, detachment, and ultimately apoptosis in human and mouse cells. (E)-2-Hexadecenal activates the MLK3 signaling pathway, phosphorylating MKK4/7 and JNK, subsequently activating downstream targets of JNK, such as c-Jun phosphorylation, cytochrome c release, Bax activation, Bid cleavage, and Bim translocation to mitochondria. (E)-2-Hexadecenal has potential applications in research related to sphingolipid signaling pathways .

RAP-103	CCR	Neurological Disease
RAP-103 is an orally active CCR antagonist that provides potent synaptic protection by inhibiting and reversing cytoskeletal changes induced by PrPC/NOX signaling. RAP-103 is potentially useful in Alzheimer's disease (AD) research .

PF-3758309 hydrochloride PF-03758309 hydrochloride	PAK Apoptosis	Cancer
PF-3758309 (PF-03758309) hydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (K_d= 2.7 nM; K_i=18.7 nM). PF-3758309 hydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .

PF-3758309 dihydrochloride PF-03758309 dihydrochloride	PAK Apoptosis	Cancer
PF-3758309 (PF-03758309) dihydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (K_d= 2.7 nM; K_i=18.7 nM). PF-3758309 dihydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .

ROCK2-IN-10	ROCK STAT	Cancer
ROCK2-IN-10 is a potent and selective ROCK2 inhibitor (IC₅₀ = 0.020 μM) with 41-fold selectivity over isoform ROCK1. ROCK2-IN-10 inhibits metastasis by disrupting the cytoskeleton, independent of proliferative suppression. ROCK2-IN-10 shows superior inhibitory potency against cancer cell metastasis, which closely related to the suppression of STAT3 phosphorylation. ROCK2-IN-10 can be used for breast cancer metastasis research .

18:0-20:4 PI(3,4,5)P3 sodium	Drug Derivative	Others
18:0-20:4 PI(3,4,5)P3 (sodium) is an analogue of phosphatidylinositol. Protein-binding to PtdIns-(3,4,5)-P3 is important for cytoskeletal rearrangements and membrane trafficking. PtdIns-(3,4,5)-P3 is resistant to cleavage by PI-specific PLC .

C18 LPA PA(18:0e/0:0)	G Protein-coupled Receptor Kinase (GRK) Calcium Channel	Cardiovascular Disease Cancer
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.

DHI1	CDK Wee1 Checkpoint Kinase (Chk)	Cancer
DHI1 is an anti-leukemia agent with high selectivity for Jurkat (IC₅₀ = 21.83 μM) and HL-60 (IC₅₀ = 19.14 μM) leukemia cells and has low toxicity to non-cancerous cells. DHI1 can induce G2/M phase cell arrest in Jurkat and HL-60 leukemia cells, as well as S phase arrest in HL-60 cells, and has significant effects on cell cycle signaling molecules Wee1, cyclin B1, cdc2 on Tyr15, and Chk1. DHI1 inhibits the migration and invasion of Jurkat and HL-60 cells by disrupting cytoskeletal actin filaments. DHI1 can be used to study hematological malignancies .

Human CXCR3 mRNA	mRNA	Inflammation/Immunology
Human CXCR3 mRNA encodes the human C-X-C motif chemokine receptor 3 (CXCR3) protein, G protein-coupled receptor. Chemokines bind to CXCR3 protein can induce cellular responses that are involved in leukocyte traffic, integrin activation, cytoskeletal changes and chemotactic migration.

FIPI hydrochloride 5-Fluoro-2-indolyl deschlorohalopemide hydrochloride	Phospholipase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
FIPI hydrochloride is a phospholipase D (PLD) inhibitor with an IC₅₀ for PLD1 and PLD2 of about 25 nM. FIPI hydrochloride regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI hydrochloride can be used in cancer research. In addition, FIPI hydrochloride can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .

Fludioxonil-13C3 CGA-173506-¹³C₃	Isotope-Labeled Compounds Fungal Apoptosis	Infection Cancer
Fludioxonil- ¹³C₃ (CGA-173506- ¹³C₃) is ¹³C labeled Fludioxonil. Fludioxonil (CGA-173506) is a phenylpyrrole-type fungicide with oral activity that can inhibit the growth of S. sclerotiorum. Fludioxonil promotes tumor growth and metastasis, and induces cardiac toxicity. Fludioxonil causes cytoskeletal disruption, DNA damage, and apoptosis in mouse glioma cells .

Nocarnickelamide B	ROCK Myosin	Others
Nocarnickelamide B (Compound 2) is a linear peptide and ROCK1/2 inhibitor. Nocarnickelamide B exhibits dual inhibitory activity against ROCK1 and ROCK2 with IC₅₀s of 14.9 μM and 21.9 μM, respectively. Nocarnickelamide B binds to the ATP-binding site. Nocarnickelamide B inhibits the activation of ROCK-regulated cytoskeletal contraction markers such as the myosin light chain. Nocarnickelamide B is potential for glaucoma reasearch .

IKP-104	Microtubule/Tubulin	Cancer
IKP-104 is a microtubule/tubulin inhibitor (IC₅₀ = 1.31 μM). IKP-104 arrests cells in mitosis and the M phase by inhibiting microtubule polymerization and inducing cytoskeletal microtubule depolymerization. IKP-104 inhibits the growth of mouse and human tumor cell lines. IKP-104 exhibits anti-tumor effects in mouse ascites tumors and lung cancer models. IKP-104 is useful in the research of cancers such as leukemia, lung cancer and melanoma .

1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium	Biochemical Assay Reagents
1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium is a kind of activity that promotes platelet aggregation and stimulates smooth muscle contraction. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can enhance cell chemotaxis and cytoskeletal rearrangement. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can also promote Ca2+ mobilization and neurotransmitter release. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium also has a certain effect on cell proliferation.

FtsZ-IN-4	Bacterial	Infection
FtsZ-IN-4 is an orally active FtsZ (filamenting temperature-sensitive mutant Z) inhibitor, exhibits excellent antibacterial activity. FtsZ-IN-4 shows good pharmaceutical properties with low cytotoxicity (CC₅₀ >20 μg/mL) .

2-Hexadecenal (E/Z)-16:1 Aldehyde	Apoptosis Reactive Oxygen Species (ROS)	Metabolic Disease
2-Hexadecenal, a long-chain fatty aldehyde, is a byproduct of sphingolipid metabolism, involved in cytoskeletal reorganization, DNA damage, and apoptosis. 2-Hexadecenal regulates ROS production and induces apoptosis in polymorphonuclear leucocytes.

2-Hexadecenal-d5 16:1 Aldehyde-d₅	Isotope-Labeled Compounds	Metabolic Disease
2-Hexadecenal-d₅ is the deuterated 2-Hexadecenal. 2-Hexadecenal, a long-chain fatty aldehyde, is a byproduct of sphingolipid metabolism, involved in cytoskeletal reorganization, DNA damage, and apoptosis.

E8431	PDGFR Ras	Metabolic Disease
E8431 is a DCSTAMP antagonist. DCSTAMP is a key fusion protein that coordinates cell-cell fusion during osteoclastogenesis. E8431 inhibits the cytoskeleton reorganization mediated by the RAP1B-RAC1 signaling pathway. E8431 has the ability to inhibit pre-fusion of osteoclasts and, while inhibiting bone resorption, stimulates the secretion of PDGFBB, thereby stimulating the process of bone and blood vessel formation. E8431 effectively reduces bone loss in a mouse model caused by ovariectomy. E8431 can be used for the study of osteoporosis .

CK37	Choline Kinase p38 MAPK PI3K Akt Arp2/3 Complex PERK	Cancer
CK37 is a competitive choline kinase-α inhibitor. CK37 inhibits purified recombinant human choline kinase-α activity. CK37 suppresses MAPK and PI3K/AKT signaling, disrupts actin cytoskeletal organization. CK37 diminishs activating phosphorylations of ERK. CK37 exhibits anticancer activity against cervical cancer, melanoma, Lewis lung carcinoma, lung adenocarcinoma, breast cancer, and leukemia .

BAY-876 (Standard)	Reference Standards GLUT Disulfidptosis	Cancer
BAY-876 (Standard) is the analytical standard of BAY-876 (HY-100017). This product is intended for research and analytical applications. BAY-876, a chemical probe, is an orally active and selective glucose transporter 1 (GLUT1) inhibitor with an IC50 of 2 nM. BAY-876 is >130-fold more selective for GLUT1 than GLUT2, GLUT3, and GLUT4. BAY-876 is also a potent blocker of glycolytic metabolism and ovarian cancer growth. In addition, BAY-876 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .

ROCK2-IN-14	ROCK	Inflammation/Immunology
ROCK2-IN-14 is an orally active, selective ROCK2 inhibitor (IC₅₀=4.8 nM) with 212-fold selectivity over ROCK1 (IC₅₀=1.01 μM). By inhibiting the ROCK2/S100A9 signaling pathway, ROCK2-IN-14 downregulates S100A9 expression, inhibits NM2 phosphorylation and restores cytoskeletal abnormalities. Furthermore, ROCK2-IN-14 reduces inflammatory cytokine levels, alleviates skin inflammation and exerts anti-inflammatory activity. ROCK2-IN-14 also significantly inhibits ear thickening in a mouse model of atopic dermatitis (AD), and decreases the levels of IgE, TNF-α, IL-6 and TSLP. ROCK2-IN-14 can be used for research on atopic dermatitis .

Bromuconazole	Fungal Apoptosis Caspase Reactive Oxygen Species (ROS) MDM-2/p53 SOD Bcl-2 Family PERK JNK p38 MAPK	Cardiovascular Disease Infection Endocrinology Cancer
Bromuconazole is a triazole fungicide with oral efficacy and blood-brain barrier permeability . Bromuconazole protects crops from various fungal contaminations. Bromuconazole exhibits cytotoxicity against a variety of cancer cells, induces G0/G1 cell cycle arrest and inhibits DNA synthesis in cancer cells, and triggers cytoskeletal structural disorder, genotoxic damage, apoptotic (apoptosis) cell death, and mitochondrial membrane depolarization. Bromuconazole activates caspase-3, induces excessive production of ROS, p53 and Bax, lipid peroxidation, increased activities of SOD and CAT, and downregulates Bcl-2. By upregulating p-ERK1/2 and p-JNK, Bromuconazole disrupts the MAPK signaling pathway, impairs the cellular stress response of human trophoblast cells and endometrial cells, and damages the implantation process . Bromuconazole is applicable to research related to glioma, colon cancer, reproductive injury (implantation dysfunction), and cardiac dysfunction .

SP-6-27	Microtubule/Tubulin Apoptosis Caspase Bcl-2 Family	Cancer
SP-6-27 is a tubulin depolymerizing agent that binds to the colchicine site of β-tubulin. SP-6-27 induces G₂/M cell cycle arrest in ovarian cancer cells. SP-6-27 enhances intrinsic apoptosis in ovarian cancer cells through upregulation of Bax, Apaf-1, caspase-6, caspase-9, and caspase-3. SP-6-27 reduces ovarian cancer cell migration. SP-6-27 inhibits capillary tube formation by human umbilical vein endothelial cells. SP-6-27 shows minimum cytotoxicity to normal ovarian epithelia. SP-6-27 shows enhanced cytotoxicity in chemo-sensitive/resistant ovarian cancer cells when combined with Cisplatin (HY-17394). SP-6-27 can be used for the research of ovarian cancer .

Cat. No.	Product Name

HY-L060

Cytoskeleton Compound Library	2,148 compounds
The cytoskeleton is responsible for contraction, cell motility, movement of organelles and vesicles through the cytoplasm, cytokinesis, intracellular signal transduction, and many other functions that are essential for cellular homeostasis and survival. It accomplishes these tasks through three basic structures: F-actin, microtubules, and intermediate filaments (IFs). The cytoskeleton is a dynamic structure where the three major filaments and tubules are under the influence of proteins that regulate their length, state of polymerization, and level of cross-linking. Since cytoskeleton is involved in virtually all cellular processes, cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes, including several cardiovascular disease syndromes, neurodegeneration, cancer, liver cirrhosis, pulmonary fibrosis, and blistering skin diseases. MCE designs a unique collection of 2,148 cytoskeleton-related compounds mainly focusing on the key targets in the cytoskeleton signal pathway and can be used in the research of cytoskeleton signal pathway and related diseases.

Cytoskeleton Compound Library

2,148 compounds

The cytoskeleton is responsible for contraction, cell motility, movement of organelles and vesicles through the cytoplasm, cytokinesis, intracellular signal transduction, and many other functions that are essential for cellular homeostasis and survival. It accomplishes these tasks through three basic structures: F-actin, microtubules, and intermediate filaments (IFs). The cytoskeleton is a dynamic structure where the three major filaments and tubules are under the influence of proteins that regulate their length, state of polymerization, and level of cross-linking. Since cytoskeleton is involved in virtually all cellular processes, cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes, including several cardiovascular disease syndromes, neurodegeneration, cancer, liver cirrhosis, pulmonary fibrosis, and blistering skin diseases.

MCE designs a unique collection of 2,148 cytoskeleton-related compounds mainly focusing on the key targets in the cytoskeleton signal pathway and can be used in the research of cytoskeleton signal pathway and related diseases.

Cat. No.	Product Name	Type

HY-D2871

DAyne	Fluorescent Dyes
DAyne is a Dopamine (DA)-mimetic probe. DAyne covalently binds to proteins modified by dopamine oxidation products (e.g., dopaquinone, DQ) to form adducts. DAyne is promising for research of Parkinson’s disease (PD), particularly neurotoxicity, protein modification, and related pathways (e.g., endoplasmic reticulum stress, cytoskeletal instability) caused by dopamine dysregulation .

Cat. No.	Product Name	Type

HY-112624I

Dextran T3 (MW 3,000)

Dextran 3; Dextran D3; Dextran T3(MW 2400-3600)

Biochemical Assay Reagents

Dextran T3 (Dextran 3; Dextran T3(MW 2400-3600)) is a neural tracer and intestinal permeability probe that can move anterogradely and retrogradely in neuronal axons by passive diffusion. Dextran T3 (MW 3,000) is able to permeate across the intestinal epithelial cell membrane in the presence of cholera toxin-induced cytoskeletal disturbance. Dextran T3 (MW 3,000) is used as a fluorescent marker to rapidly label developing neurons (such as Xenopus retinal ganglion cells) and to assess intestinal barrier function. It can be used to study axonal transport in neuroanatomy and permeability changes in intestinal pathophysiology. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .

HY-W339833

1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium

Biochemical Assay Reagents

1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium is a kind of activity that promotes platelet aggregation and stimulates smooth muscle contraction. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can enhance cell chemotaxis and cytoskeletal rearrangement. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can also promote Ca2+ mobilization and neurotransmitter release. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium also has a certain effect on cell proliferation.

Cat. No.	Product Name	Target	Research Area

HY-W011258

H-Tyr-Phe-OH L-Tyrosyl-L-phenylalanine	Xanthine Oxidase Angiotensin-converting Enzyme (ACE)	Inflammation/Immunology Cancer
H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells .

HY-P11319

RAP-103	CCR	Neurological Disease
RAP-103 is an orally active CCR antagonist that provides potent synaptic protection by inhibiting and reversing cytoskeletal changes induced by PrPC/NOX signaling. RAP-103 is potentially useful in Alzheimer's disease (AD) research .

Species:	Human (2)
Tag:	His (2) Myc (1)
Source:	HEK293 (1) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P71668

	KRT18 Protein, Human (HEK293, His) Cell proliferation inducing gene 46 protein; Cell proliferation inducing protein 46 ; Keratin D ; keratin, type I cytoskeletal 18; Keratin-18; Krt18	Human	HEK293
	The KRT18 protein is a heterotetramer with KRT8 that has multiple roles, including uptake of thrombin-antithrombin complexes and assisting in the delivery of mutated CFTR to the plasma membrane. It cooperates with KRT8 in IL-6-mediated barrier protection and interacts with PLEC isoform 1C. KRT18 Protein, Human (HEK293, His) is the recombinant human-derived KRT18 protein, expressed by HEK293 , with N-10*His labeled tag.

HY-P72052

	KRT8 Protein, Human (sf9, His-Myc) CARD2; CK 8; CK-8; CK8; CYK8; CYKER; Cytokeratin endo A; Cytokeratin-8; DreK8; EndoA; K2C8; K2C8_HUMAN; K8; Keratin 8; Keratin type II cytoskeletal 8 ; Keratin; type II cytoskeletal 8; Keratin-8; KO; Krt 2.8; KRT8; MGC118110; MGC174782; MGC53564; MGC85764; sb:cb186; Type-II keratin Kb8	Human	Sf9 insect cells
	The KRT8 protein, in cooperation with KRT19, critically links the contractile apparatus of the striated rib muscle to dystrophin. This heterotetramer consists of two type I keratins and two type II keratins, forming a heterodimer with KRT18. KRT8 Protein, Human (sf9, His-Myc) is the recombinant human-derived KRT8 protein, expressed by Sf9 insect cells , with N-10*His, C-Myc labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (26) Rabbit (33)
Reactivity:	Human (59) Rat (26) Mouse (28) Hamster (2)
Application:	IHC-P (53) ICC/IF (41) mIHC (1) IF-Tissue (11) IP (11) IHC-F (14) WB (50) FC (13) ELISA (23)
Isotype:	IgG2a,IgG/Kappa (1) IgG (36) IgG2b,IgG/Kappa (1) IgG1 (10) IgG2a (4) IgG/Kappa (2) IgG2b (4)
Conjugation:	Non-conjugated (57)
Clonality:	Polyclonal (3) Monoclonal (50) Recombinant (17)
Modification:	Phosphorylated (1) Unmodified (51)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82926

	Cytokeratin 2e Antibody (YA2671) KRT2; KRT76; KRT3; KRT5; KRT6A; KRT6B; KRT6C; KRT71; KRT72; KRT73; KRT74; KRT75; KRT79; KRT8; KRT84; Keratin; type II cytoskeletal 2 epidermal; Keratin; type II cytoskeletal 2 oral; Keratin; type II cytoskeletal 3; Keratin; type II cytoskeletal 5; Keratin; type II cytoskeletal 6A; Keratin; type II cytoskeletal 6B; Keratin; type II cytoskeletal 6C; Keratin; type II cytoskeletal 71; Keratin; type II cytoskeletal 72; Keratin; type II cytoskeletal 73; Keratin; type II cytoskeletal 74	WB, IHC-P	Human
	Cytokeratin 2e Antibody (YA2671) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 2e.

HY-P83259

	Cytokeratin 12 Antibody (YA3004) K12; Keratin 12; KRT12; type I cytoskeletal 12	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	Cytokeratin 12 Antibody (YA3004) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 12.

HY-P82789

	Cytokeratin 17 Antibody (YA2534) Keratin; type I cytoskeletal 17; Cytokeratin-17; CK-17; Keratin-17; K17	WB, IHC-P, IP	Human
	Cytokeratin 17 Antibody (YA2534) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 17.

HY-P86031

	Cytokeratin 10 Antibody (YA5723) Keratin, type I cytoskeletal 10; Cytokeratin-10; CK-10; Keratin-10; K10;	IHC-P, ICC/IF, ELISA	Human
	Cytokeratin 10 Antibody (YA5723) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin 10.

HY-P86032

	Cytokeratin 15 Antibody (YA5724) Keratin, type I cytoskeletal 15; Cytokeratin-15; CK-15; Keratin-15; K15;	IHC-P, ELISA	Human
	Cytokeratin 15 Antibody (YA5724) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin 15.

HY-P82131

	Cytokeratin 14 Antibody (YA1876) KRT14; Keratin; type I cytoskeletal 14; Cytokeratin-14; CK-14; Keratin-14; K14	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	Cytokeratin 14 Antibody (YA1876) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 14.

HY-P86129

	Cytokeratin 20 Antibody (YA5821) Keratin, type I cytoskeletal 20; Cytokeratin-20; CK-20; Keratin-20; K20; Protein IT;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Rat
	Cytokeratin 20 Antibody (YA5821) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 20.

HY-P86033

	Cytokeratin 20 Antibody (YA5725) Keratin, type I cytoskeletal 20; Cytokeratin-20; CK-20; Keratin-20; K20; Protein IT;	IHC-P, ELISA	Human, Mouse, Rat
	Cytokeratin 20 Antibody (YA5725) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Cytokeratin 20.

HY-P86455

	Cytokeratin 19 Antibody (YA6147) KRT19; Keratin, type I cytoskeletal 19; Cytokeratin-19; CK-19; Keratin-19; K19	WB, IHC-P, ICC/IF, FC, IF-Tissue, mIHC	Human, Mouse, Rat
	Cytokeratin 19 Antibody (YA6147) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 19.

HY-P82789A

	Cytokeratin 17 Antibody (YA2534)(PBS only) Keratin; type I cytoskeletal 17; Cytokeratin-17; CK-17; Keratin-17; K17	WB, IHC-P, IP	Human
	Cytokeratin 17 Antibody (YA2534) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 17.

HY-P85903

	Cytokeratin 17 Antibody (YA5595) 39.1; CK 17; CK-17; CytokeRatin-17; K17; K1C17_HUMAN; KeRatin 17; keRatin 17 epitope S1; keRatin 17 epitope S2; keRatin 17 epitope S4; KeRatin 17, type I; KeRatin; KeRatin type I cytoskeletal 17; keRatin, type i cytoskeletal 17 [version 1]; KeRatin-17; KRT17; PC; PC2; PCHC1; type I cytoskeletal 17	IHC-P, WB, ICC/IF, ELISA	Human, Mouse, Rat
	Cytokeratin 17 Antibody (YA5595) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin 17.

HY-P82112

	Cytokeratin 10 Antibody (YA1857) KRT10; KPP; Keratin; type I cytoskeletal 10; Cytokeratin-10; CK-10; Keratin-10; K10	WB, IHC-P	Human, Hamster, Mouse, Rat
	Cytokeratin 10 Antibody (YA1857) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 10.

HY-P85117

	Cytokeratin 15 Antibody (YA4809) KRT15; KRTB; Keratin; type I cytoskeletal 15; Cytokeratin-15; CK-15; Keratin-15; K15	WB, IHC-P, ICC/IF, FC, ELISA	Human
	Cytokeratin 15 Antibody (YA4809) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Cytokeratin 15.

HY-P89398M

	Cytokeratin 19 Antibody (AF488) (YA6147) KRT19; Keratin, type I cytoskeletal 19; Cytokeratin-19; CK-19; Keratin-19; K19	ICC/IF, FC, IF-Tissue	Human, Mouse
	Cytokeratin 19 Antibody (YA6147) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 19.

HY-P81266

	Cytokeratin 16 Antibody (YA948) KRT16; KRT16A; Keratin; type I cytoskeletal 16; Cytokeratin-16; CK-16; Keratin-16; K16	WB, IHC-P	Human, Mouse, Rat
	Cytokeratin 16 Antibody (YA948) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin 16.

HY-P81266A

	Cytokeratin 16 Antibody (YA949) KRT16; KRT16A; Keratin; type I cytoskeletal 16; Cytokeratin-16; CK-16; Keratin-16; K16	WB, IHC-P	Human
	Cytokeratin 16 Antibody (YA949) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 16.

HY-P82112A

	Cytokeratin 10 Antibody (YA1857)(PBS only) KRT10; KPP; Keratin; type I cytoskeletal 10; Cytokeratin-10; CK-10; Keratin-10; K10	WB, IHC-P	Human, Hamster, Mouse, Rat
	Cytokeratin 10 Antibody (YA1857) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 10.

HY-P81266AA

	Cytokeratin 16 Antibody (YA949)(PBS only) KRT16; KRT16A; Keratin; type I cytoskeletal 16; Cytokeratin-16; CK-16; Keratin-16; K16	WB, IHC-P	Human
	Cytokeratin 16 Antibody (YA949) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 16.

HY-P85906

	Cytokeratin 4 Antibody (YA5598) CK 4; CK-4; CK4; CYK4; Cytokeratin 4; CytokeRatin-4; CytokeRatin4; FLJ31692; K2C4_HUMAN; K4; KeRatin 4; KeRatin; KeRatin type II cytoskeletal 4; KeRatin-4; KeRatin4; KRT 4; Krt4; type II cytoskeletal 4; Type-II keRatin Kb4	IHC-P, WB, ICC/IF, ELISA	Human
	Cytokeratin 4 Antibody (YA5598) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Cytokeratin 4.

HY-P86663

	Cytokeratin 14 Antibody (YA6355) Cytokeratin 14; CK 14; Cytokeratin14; Cytokeratin-14; Dowling Meara; ebs3; Epidermolysis bullosa simplex; k14; Keratin 14; Keratin type I cytoskeletal 14; Keratin14; Koebner; Krt 14; krt14; EBS3; EBS4; NFJ; Keratin, type I cytoskeletal 14; K1C14_HUMAN.	IHC-P, IHC-F, IF-Tissue	Human, Mouse, Rat
	Cytokeratin 14 Antibody (YA6355) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 14.

HY-P82950

	Cytokeratin 13 Antibody (YA2695) Keratin; type I cytoskeletal 13; Krt1-13; Cytokeratin 13; CK13; Keratin 13; KRT13; WSN2	WB, IHC-P, ICC/IF	Human
	Cytokeratin 13 Antibody (YA2695) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 13.

HY-P83260

	Cytokeratin 8 Antibody (YA3005) KRT8; CYK8; Keratin; type II cytoskeletal 8; Cytokeratin-8; CK-8; Keratin-8; K8; Type-II keratin Kb8	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse
	Cytokeratin 8 Antibody (YA3005) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 8.

HY-P83702

	Cytokeratin 17 Antibody (YA3438) 39.1 antibody; CK 17 antibody; CK17 antibody; CK-17 antibody; Cytokeratin-17 antibody; K17 antibody; K1C17_HUMAN antibody; Keratin 17 antibody; keratin 17 epitope S1 antibody; keratin 17 epitope S2 antibody; keratin 17 epitope S4 antibody; Keratin 17, type I antibody; Keratin antibody; Keratin type I cytoskeletal 17 antibody; keratin, type i cytoskeletal 17 [version 1] antibody; Keratin-17 antibody; KRT17 antibody; PC antibody; PC2 antibody; PCHC1 antibody; type I cytoskeletal 17 antibody;	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	Cytokeratin 17 Antibody (YA3438) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 17.

HY-P85900

	Cytokeratin 13 Antibody (YA5592) 47 kDa cytokeRatin; CK-13; CK13; Cytokeratin 13; CytokeRatin-13; K13; K1C13_HUMAN; Ka13; KeRatin 13; KeRatin; keRatin type I cytoskeletal 13; KeRatin-13; Krt-1.13; Krt1-13; KRT13; MGC161462; MGC3781; type I cytoskeletal 13; Type I keRatin Ka13; WSN2	IHC-P, WB, ICC/IF, ELISA	Human
	Cytokeratin 13 Antibody (YA5592) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin 13.

HY-P86552

	Cytokeratin 5 Antibody (YA6244) KRT5; Keratin; type II cytoskeletal 5; 58 kDa cytokeratin; Cytokeratin-5; CK-5; Keratin-5; K5; Type-II keratin Kb5	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Cytokeratin 5 Antibody (YA6244) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 5.

HY-P82890

	Phospho-Cytokeratin 8 (Ser23) Antibody (YA2635) KRT8; CYK8; Keratin; type II cytoskeletal 8; Cytokeratin-8; CK-8; Keratin-8; K8; Type-II keratin Kb8	WB, IHC-F, IHC-P, ICC/IF, IP	Human
	Phospho-Cytokeratin 8 (Ser23) Antibody (YA2635) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Cytokeratin 8 (Ser23).

HY-P86485

	Cytokeratin 7 Antibody (YA6177) CK 7; CK-7; CK7; Cytokeratin 7; Cytokeratin-7; D15Wsu77e; K2C7; K2C7_HUMAN; K7; Keratin 7; Keratin 7, type II; Keratin type II cytoskeletal 7; Keratin, 55K type II cytoskeletal; Keratin, simple epithelial; Keratin, simple epithelial type I, K7; Keratin, type II cytoskeletal 7; Keratin-7; Krt2-7; KRT7; MGC11625; MGC129731; MGC3625; Sarcolectin; SCL; Type II mesothelial keratin K7; Type-II keratin Kb7	WB, IHC-P, ICC/IF, ELISA	Human, Mouse, Rat
	Cytokeratin 7 Antibody (YA6177) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 7.

HY-P81183

	Cytokeratin 19 Antibody 40 kDa keratin intermediate filament; CK 19; ck19; CK19; CK-19; KRT19; Cytokeratin19; Cytokeratin-19; k19; k1cs; Keratin 19; Keratin-19; Keratin type I 40 kD; Keratin type i 40kD; Keratin type I cytoskeletal 19; krt19; mgc15366; K1C19_HUMAN; Keratin, type I cytoskeletal 19; Keratin, type I, 40 kd.	WB, ELISA, IHC-P, IHC-F, FC, ICC/IF	Human
	Cytokeratin 19 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Cytokeratin 19.

HY-P85905

	Cytokeratin 20 Antibody (YA5597) CD20; CK 20; CK-20; CK20; CytokeRatin-20; CytokeRatin20; K1C20_HUMAN; K20; KA20; KeRatin 20; keRatin 20, type I; keRatin 21, Rat, homolog of; KeRatin; KeRatin type I cytoskeletal 20; KeRatin-20; KeRatin20; KRT 20; KRT 21; KRT20; KRT21; MGC35423; OTTHUMP00000164518; Protein IT; type I cytoskeletal 20	IHC-P, WB, ICC/IF, ELISA	Human, Mouse, Rat
	Cytokeratin 20 Antibody (YA5597) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Cytokeratin 20.

HY-P85943

	Cytokeratin 19/10 Antibody (YA5635) 40 kDa keRatin intermediate filament; CK 19; CK-19; CK19; Cytokeratin 19; CytokeRatin-19; K19; K1C19_HUMAN; K1CS; KeRatin 19; KeRatin type I 40 kD; KeRatin type I 40kD; KeRatin type I cytoskeletal 19; KeRatin, type I cytoskeletal 19; KeRatin, type I, 40 kd; KeRatin-19; KRT19; MGC15366	IHC-P, WB, ICC/IF, ELISA	Human
	Cytokeratin 19/10 Antibody (YA5635) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin 19/10.

HY-P86497

	Cytokeratin 18 Antibody (YA6189) KRT18; CYK18; PIG46; Keratin, type I cytoskeletal 18; Cell proliferation-inducing gene 46 protein; Cytokeratin-18; CK-18; Keratin-18; K18	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Cytokeratin 18 Antibody (YA6189) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 18.

HY-P82890A

	Phospho-Cytokeratin 8 (Ser23) Antibody (YA2635)(PBS only) KRT8; CYK8; Keratin; type II cytoskeletal 8; Cytokeratin-8; CK-8; Keratin-8; K8; Type-II keratin Kb8	WB, IHC-F, IHC-P, ICC/IF, IP	Human
	Phospho-Cytokeratin 8 (Ser23) Antibody (YA2635) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Cytokeratin 8 (Ser23).

HY-P81183A

	Cytokeratin 19 Antibody(PBS only) 40 kDa keratin intermediate filament; CK 19; ck19; CK19; CK-19; KRT19; Cytokeratin19; Cytokeratin-19; k19; k1cs; Keratin 19; Keratin-19; Keratin type I 40 kD; Keratin type i 40kD; Keratin type I cytoskeletal 19; krt19; mgc15366; K1C19_HUMAN; Keratin, type I cytoskeletal 19; Keratin, type I, 40 kd.	WB, IHC-P, IHC-F, ICC/IF, FC, ELISA	Human, Mouse
	Cytokeratin 19 Antibody(PBS only) is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Cytokeratin 19.

HY-P81250

	Cytokeratin 19 Antibody (YA924) 40 kDa keratin intermediate filament; CK 19; ck19; CK19; CK-19; KRT19; Cytokeratin19; Cytokeratin-19; k19; k1cs; Keratin 19; Keratin-19; Keratin type I 40 kD; Keratin type i 40kD; Keratin type I cytoskeletal 19; krt19; mgc15366; K1C19_HUMAN; Keratin, type I cytoskeletal 19; Keratin, type I, 40 kd	WB, IHC-P, IHC-F, ICC/IF	Human
	Cytokeratin 19 Antibody (YA924) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 19.

HY-P85902

	Cytokeratin 16 Antibody (YA5594) CK 16; CK-16; CK16; Cytokeratin 16; CytokeRatin-16; CytokeRatin16; FNEPPK; Focal non epidermolytic palmoplantar keRatoderma; K 16; K16; K1C16_HUMAN; K1CP; KeRatin 1 type I; KeRatin 16; KeRatin; KeRatin type I cytoskeletal 16; KeRatin-16; KeRatin16; KRT 16; Krt16; KRT16A; NEPPK; PC1; type I cytoskeletal 16	IHC-P, WB, ICC/IF, ELISA	Human
	Cytokeratin 16 Antibody (YA5594) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Cytokeratin 16.

HY-P86504

	Cytokeratin 8 Antibody (YA6196) CARD2; CK 8; CK-8; CK8; CYK8; CYKER; Cytokeratin endo A; Cytokeratin-8; DreK8; EndoA; K2C8; K2C8_HUMAN; K8; Keratin 8; Keratin type II cytoskeletal 8; Keratin, type II cytoskeletal 8; Keratin-8; KO; Krt 2.8; KRT8; MGC118110; MGC174782; MGC53564; MGC85764; sb:cb186; Type-II keratin Kb8	WB, IHC-P, ICC/IF, IP, FC, IF-Tissue	Human, Mouse, Rat
	Cytokeratin 8 Antibody (YA6196) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 8.

HY-P89399M

	Cytokeratin 8 Antibody (AF488) (YA6196) CARD2; CK 8; CK-8; CK8; CYK8; CYKER; Cytokeratin endo A; Cytokeratin-8; DreK8; EndoA; K2C8; K2C8_HUMAN; K8; Keratin 8; Keratin type II cytoskeletal 8; Keratin, type II cytoskeletal 8; Keratin-8; KO; Krt 2.8; KRT8; MGC118110; MGC174782; MGC53564; MGC85764; sb:cb186; Type-II keratin Kb8	ICC/IF, FC, IF-Tissue	Human
	Cytokeratin 8 Antibody (YA6196) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 8.

HY-P85904

	Cytokeratin 8/18 Antibody (YA5596) CARD2; CK 8; CK-8; CK8; CYK8; CYKER; Cytokeratin endo A; CytokeRatin-8; DreK8; EndoA; K2C8; K2C8_HUMAN; K8; KeRatin 8; KeRatin type II cytoskeletal 8; KeRatin, type II cytoskeletal 8; KeRatin-8; KO; Krt 2.8; KRT8; MGC118110; MGC174782; MGC53564; MGC85764; sb:cb186; Type-II keRatin Kb8; CK 18; CK-18; CK18; CYK18; Cytokeratin 18; Cytokeratin endo B; CytokeRatin-18; K 18; K18; K1C18_HUMAN; KA18; KeRatin 18; KeRatin 18, type I; KeRatin D; keRatin, type I cytoskeletal 18; KeRatin-18; Krt18	IHC-P, WB, ICC/IF, ELISA	Human, Mouse, Rat
	Cytokeratin 8/18 Antibody (YA5596) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Cytokeratin 8/18.

HY-P81748

	Cytokeratin 15 Antibody (YA1493) CK-15; CK15; cytokeratin15; K15; K1C15; K1CO; keratin 15; Keratin-15; keratin-15; beta; KRT15; KRTB; type I cytoskeletal 15	WB, IHC-P, ICC/IF, FC	Human, Mouse
	Cytokeratin 15 Antibody (YA1493) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 15.

HY-P81267

	Cytokeratin 7 Antibody (YA950) CK 7; CK-7; ck7; Cytokeratin 7; Cytokeratin-7; Cytokeratin7; D15Wsu77e; K2C7; K2C7_HUMAN; K7; Keratin 55k type ii cytoskeletal; Keratin 7; Keratin simple epithelial type 1 k7; Keratin type II cytoskeletal 7	WB, ICC/IF	Human
	Cytokeratin 7 Antibody (YA950) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Cytokeratin 7.

HY-P81267A

	Cytokeratin 7 Antibody (YA951) CK 7; CK-7; ck7; Cytokeratin 7; Cytokeratin-7; Cytokeratin7; D15Wsu77e; K2C7; K2C7_HUMAN; K7; Keratin 55k type ii cytoskeletal; Keratin 7; Keratin simple epithelial type 1 k7; Keratin type II cytoskeletal 7	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	Cytokeratin 7 Antibody (YA951) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin 7.

HY-P81267B

	Cytokeratin 7 Antibody (YA952) CK 7; CK-7; ck7; Cytokeratin 7; Cytokeratin-7; Cytokeratin7; D15Wsu77e; K2C7; K2C7_HUMAN; K7; Keratin 55k type ii cytoskeletal; Keratin 7; Keratin simple epithelial type 1 k7; Keratin type II cytoskeletal 7	WB, ICC/IF, IP	Human
	Cytokeratin 7 Antibody (YA952) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 7.

HY-P85901

	Cytokeratin 15 Antibody (YA5593) AI528832; CK 15; CK-15; CK15; CytokeRatin-15; CytokeRatin15; K15; K1C15_HUMAN; K1CO; Ka15; KeRatin 15; KeRatin 15 basic; KeRatin 15 beta; KeRatin; KeRatin complex 1 acidic gene 15; KeRatin type I cytoskeletal 15; KeRatin-15; KeRatin15; KRT 15; Krt1-15; KRT15; KRTB; KRTL15; Type I cytoskeletal 15; Type I keRatin Ka15	IHC-P, WB, ICC/IF, ELISA	Human
	Cytokeratin 15 Antibody (YA5593) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin 15.

HY-P81181

	Cytokeratin 18 Antibody 1 Publications Verification K1C18_HUMAN; Keratin, type I cytoskeletal 18; KRT18; CYK18; Cell proliferation-inducing gene 46 protein; Cytokeratin-18 (CK-18); Keratin-18 (K18); PIG46; Keratin 18;	WB, ELISA, IHC-P, IHC-F, FC, ICC/IF	Human, Mouse, Rat
	Cytokeratin 18 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Cytokeratin 18.

HY-P82920

	Cytokeratin 1 Antibody (YA2665) 67 kDa cytokeratin; CK1; EHK; Epidermolytic hyperkeratosis 1; EPPK; Hair alpha protein; K1; Keratin; KRT 1; KRT1A; NEPPK; type II cytoskeletal 1; Type-II keratin Kb1	WB	Human, Mouse, Rat
	Cytokeratin 1 Antibody (YA2665) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 1.

HY-P86723

	Cytokeratin 18 Antibody (YA6415) K1C18_HUMAN; Keratin, type I cytoskeletal 18; KRT18; CYK18; Cell proliferation-inducing gene 46 protein; Cytokeratin-18(CK-18); Keratin-18(K18); PIG46; Keratin 18;	WB, IHC-P, IHC-F, ICC/IF, IF-Tissue	Human, Mouse, Rat
	Cytokeratin 18 Antibody (YA6415) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 18.

HY-P85826

	Cytokeratin 6 Antibody (YA5518) CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_HUMAN; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12	IHC-P, WB, ICC/IF, ELISA	Human
	Cytokeratin 6 Antibody (YA5518) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Cytokeratin 6.

HY-P85990

	Cytokeratin 6 Antibody (YA5682) CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_HUMAN; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12	IHC-P, ELISA	Human
	Cytokeratin 6 Antibody (YA5682) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Cytokeratin 6.

HY-P85907

	Cytokeratin 5/6 Antibody (YA5599) 58 kDa cytokeratin; CK-5; CK5; Cytokeratin-5; Cytokeratin5; DDD; DDD1; EBS2; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K2C5_HUMAN; K5; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; Keratin 5; Keratin; keratin complex 2, basic, gene 5; keratin, type II cytoskeletal 5; Keratin-5; Keratin5; KRT 5; Krt5; KRT5A; type II cytoskeletal 5; Type-II keratin Kb5; CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_HUMAN; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12; 58 kDa Cytokeratin antibody; CK-5 antibody; CK5 antibody; Cytokeratin-5 antibody; Cytokeratin5 antibody; DDD antibody; DDD1 antibody; EBS2 antibody; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody; K2C5_HUMAN antibody; K5 antibody; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; antibody; Keratin 5 antibody; Keratin antibody; keratin complex 2, basic, gene 5 antibody; keratin, type II cytoskeletal 5 antibody; Keratin-5 antibody; Keratin5 antibody; KRT 5 antibody; Krt5 antibody; KRT5A antibody; type II cytoskeletal 5 antibody; Type-II keratin Kb5 antibody	IHC-P, WB, ICC/IF, ELISA	Human
	Cytokeratin 5/6 Antibody (YA5599) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Cytokeratin 5/6.

HY-P85984

	Cytokeratin 5/6 Antibody (YA5676) 58 kDa cytokeratin; CK-5; CK5; Cytokeratin-5; Cytokeratin5; DDD; DDD1; EBS2; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K2C5_HUMAN; K5; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; Keratin 5; Keratin; keratin complex 2, basic, gene 5; keratin, type II cytoskeletal 5; Keratin-5; Keratin5; KRT 5; Krt5; KRT5A; type II cytoskeletal 5; Type-II keratin Kb5; CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_HUMAN; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12; 58 kDa cytokeratin antibody; CK-5 antibody; CK5 antibody; Cytokeratin-5 antibody; Cytokeratin5 antibody; DDD antibody; DDD1 antibody; EBS2 antibody; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody; K2C5_HUMAN antibody; K5 antibody; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; antibody; Keratin 5 antibody; Keratin antibody; keratin complex 2, basic, gene 5 antibody; keratin, type II cytoskeletal 5 antibody; Keratin-5 antibody; Keratin5 antibody; KRT 5 antibody; Krt5 antibody; KRT5A antibody; type II cytoskeletal 5 antibody; Type-II keratin Kb5 antibody	IHC-P, ELISA	Human
	Cytokeratin 5/6 Antibody (YA5676) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Cytokeratin 5/6.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-D2871

DAyne		Alkynes
DAyne is a Dopamine (DA)-mimetic probe. DAyne covalently binds to proteins modified by dopamine oxidation products (e.g., dopaquinone, DQ) to form adducts. DAyne is promising for research of Parkinson’s disease (PD), particularly neurotoxicity, protein modification, and related pathways (e.g., endoplasmic reticulum stress, cytoskeletal instability) caused by dopamine dysregulation .

Cat. No.	Product Name		Classification

HY-W783254

C18 LPA PA(18:0e/0:0)		Phospholipids
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.

HY-174726

Human CXCR3 mRNA		mRNA Chemokine & Receptors
Human CXCR3 mRNA encodes the human C-X-C motif chemokine receptor 3 (CXCR3) protein, G protein-coupled receptor. Chemokines bind to CXCR3 protein can induce cellular responses that are involved in leukocyte traffic, integrin activation, cytoskeletal changes and chemotactic migration.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

cytoskeletal

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products